{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T12:24:55Z","timestamp":1794745495652,"version":"4.9.1"},"reference-count":169,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T00:00:00Z","timestamp":1583366400000},"content-version":"vor","delay-in-days":370,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.jacc.2018.11.050","type":"journal-article","created":{"date-parts":[[2019,2,25]],"date-time":"2019-02-25T16:44:18Z","timestamp":1551113058000},"page":"948-963","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":429,"title":["Nonalcoholic Fatty Liver Disease and\u00a0the\u00a0Heart"],"prefix":"10.1016","volume":"73","author":[{"given":"Eric P.","family":"Stahl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devinder S.","family":"Dhindsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suegene K.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratik B.","family":"Sandesara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naga P.","family":"Chalasani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence S.","family":"Sperling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2018.11.050_bib1","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","article-title":"Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis","volume":"10","author":"Anstee","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jacc.2018.11.050_bib2","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/nyas.12016","article-title":"Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals","volume":"1281","author":"Masuoka","year":"2013","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jacc.2018.11.050_bib3","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2018.11.050_bib4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2018.11.050_bib5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jacc.2018.11.050_bib6","doi-asserted-by":"crossref","first-page":"e0173499","DOI":"10.1371\/journal.pone.0173499","article-title":"Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States","volume":"12","author":"Le","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jacc.2018.11.050_bib7","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/aje\/kws448","article-title":"Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994","volume":"178","author":"Lazo","year":"2013","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jacc.2018.11.050_bib8","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/hep.20466","article-title":"Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity","volume":"40","author":"Browning","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2018.11.050_bib9","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1053\/j.gastro.2014.11.039","article-title":"Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States","volume":"148","author":"Wong","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jacc.2018.11.050_bib10","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","article-title":"Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases","volume":"66","author":"Adams","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.jacc.2018.11.050_bib11","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1161\/ATVBAHA.107.147538","article-title":"Fatty liver: a novel component of the metabolic syndrome","volume":"28","author":"Kotronen","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2018.11.050_bib12","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.jacc.2015.06.1328","article-title":"The CardioMetabolic Health Alliance: Working Toward a New Care Model for the Metabolic Syndrome","volume":"66","author":"Sperling","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.11.050_bib13","doi-asserted-by":"crossref","first-page":"33386","DOI":"10.1038\/srep33386","article-title":"Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and meta-analysis","volume":"6","author":"Wu","year":"2016","journal-title":"Scientific Reports"},{"key":"10.1016\/j.jacc.2018.11.050_bib14","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1007\/s10620-016-4079-4","article-title":"Fibrosis assessment in nonalcoholic fatty liver disease (NAFLD) in 2016","volume":"61","author":"Kaswala","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jacc.2018.11.050_bib15","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s10620-016-4044-2","article-title":"Screening for nonalcoholic steatohepatitis in individuals with type 2 diabetes: a cost-effectiveness analysis","volume":"61","author":"Corey","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jacc.2018.11.050_bib16","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jacc.2018.11.050_bib17","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jhep.2016.04.005","article-title":"Non-alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications","volume":"65","author":"Francque","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jacc.2018.11.050_bib18","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1161\/CIRCULATIONAHA.106.652859","article-title":"Endothelial function and dysfunction: testing and clinical relevance","volume":"115","author":"Deanfield","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.11.050_bib19","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.metabol.2010.07.027","article-title":"Plasma levels of asymmetric dimethylarginine in patients with biopsy-proven nonalcoholic fatty liver disease","volume":"60","author":"Kasumov","year":"2011","journal-title":"Metabolism"},{"key":"10.1016\/j.jacc.2018.11.050_bib20","doi-asserted-by":"crossref","first-page":"e0136822","DOI":"10.1371\/journal.pone.0136822","article-title":"Dysregulated hepatic methionine metabolism drives homocysteine elevation in diet-induced nonalcoholic fatty liver disease","volume":"10","author":"Pacana","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jacc.2018.11.050_bib21","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1053\/j.gastro.2012.02.003","article-title":"Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications","volume":"142","author":"Cusi","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jacc.2018.11.050_bib22","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/hep.20781","article-title":"Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease","volume":"42","author":"Villanova","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2018.11.050_bib23","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/hep.23719","article-title":"Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites","volume":"52","author":"Neuschwander-Tetri","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2018.11.050_bib24","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.atherosclerosis.2013.01.022","article-title":"Nonalcoholic fatty liver disease and serum lipoproteins: the Multi-Ethnic Study of Atherosclerosis","volume":"227","author":"DeFilippis","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2018.11.050_bib25","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.cgh.2014.10.008","article-title":"Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile","volume":"13","author":"Siddiqui","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jacc.2018.11.050_bib26","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.jacl.2015.03.010","article-title":"Low- and high-density lipoprotein subclasses in subjects with nonalcoholic fatty liver disease","volume":"9","author":"Sonmez","year":"2015","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.jacc.2018.11.050_bib27","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1194\/jlr.P054387","article-title":"Lipoprotein subclass metabolism in nonalcoholic steatohepatitis","volume":"55","author":"Mannisto","year":"2014","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacc.2018.11.050_bib28","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/1476-511X-13-100","article-title":"Nonalcoholic steatohepatitis is associated with an atherogenic lipoprotein subfraction profile","volume":"13","author":"Corey","year":"2014","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.jacc.2018.11.050_bib29","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jhep.2016.09.022","article-title":"Bi-directional analysis between fatty liver and cardiovascular disease risk factors","volume":"66","author":"Ma","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jacc.2018.11.050_bib30","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2337\/dc08-1870","article-title":"Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women's Heart and Health Study and meta-analysis","volume":"32","author":"Fraser","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2018.11.050_bib31","doi-asserted-by":"crossref","first-page":"372","DOI":"10.2337\/dc17-1902","article-title":"Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis","volume":"41","author":"Mantovani","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2018.11.050_bib32","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ijcard.2015.08.107","article-title":"Mechanistic link between nonalcoholic fatty liver disease and cardiometabolic disorders","volume":"201","author":"Lim","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2018.11.050_bib33","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/hep.26672","article-title":"Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes","volume":"59","author":"Birkenfeld","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2018.11.050_bib34","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.plipres.2012.10.004","article-title":"Molecular mechanisms and the role of saturated fatty acids in the progression of non-alcoholic fatty liver disease","volume":"52","author":"Leamy","year":"2013","journal-title":"Prog Lipid Res"},{"key":"10.1016\/j.jacc.2018.11.050_bib35","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1464-5491.2006.01817.x","article-title":"Increased prevalence of cardiovascular disease in Type 2 diabetic patients with non-alcoholic fatty liver disease","volume":"23","author":"Targher","year":"2006","journal-title":"Diabetic Med"},{"key":"10.1016\/j.jacc.2018.11.050_bib36","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.3748\/wjg.v13.i10.1579","article-title":"Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease","volume":"13","author":"Hamaguchi","year":"2007","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jacc.2018.11.050_bib37","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1002\/hep.23135","article-title":"Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels","volume":"50","author":"Haring","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2018.11.050_bib38","first-page":"153","article-title":"Natural course of nonalcoholic fatty liver disease in southern China: a prospective cohort study","volume":"13","author":"Zhou","year":"2012","journal-title":"J\u00a0Dig Dis"},{"key":"10.1016\/j.jacc.2018.11.050_bib39","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/j.1478-3231.2011.02753.x","article-title":"The Framingham risk score and heart disease in nonalcoholic fatty liver disease","volume":"32","author":"Treeprasertsuk","year":"2012","journal-title":"Liver Int"},{"key":"10.1016\/j.jacc.2018.11.050_bib40","doi-asserted-by":"crossref","first-page":"e004973","DOI":"10.1136\/bmjopen-2014-004973","article-title":"Fatty liver predicts the risk for cardiovascular events in middle-aged population: a population-based cohort study","volume":"4","author":"Pisto","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.jacc.2018.11.050_bib41","first-page":"2101","article-title":"Prognosis of patients with a diagnosis of fatty liver--a registry-based cohort study","volume":"50","author":"Jepsen","year":"2003","journal-title":"Hepato-Gastroenterology"},{"key":"10.1016\/j.jacc.2018.11.050_bib42","doi-asserted-by":"crossref","first-page":"752","DOI":"10.2214\/AJR.13.11367","article-title":"Natural history of hepatic steatosis: observed outcomes for subsequent liver and cardiovascular complications","volume":"202","author":"Pickhardt","year":"2014","journal-title":"Am J Roentgenology"},{"key":"10.1016\/j.jacc.2018.11.050_bib43","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.2337\/dc06-2247","article-title":"Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients","volume":"30","author":"Targher","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2018.11.050_bib44","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1097\/PAS.0b013e3182254283","article-title":"Centrizonal arteries and microvessels in nonalcoholic steatohepatitis","volume":"35","author":"Gill","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jacc.2018.11.050_bib45","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.cyto.2012.05.001","article-title":"Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease","volume":"59","author":"Coulon","year":"2012","journal-title":"Cytokine"},{"key":"10.1016\/j.jacc.2018.11.050_bib46","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.arcmed.2010.12.001","article-title":"Circulating levels of vascular endothelial growth factor A and its soluble receptor in patients with biopsy-proven nonalcoholic fatty liver disease","volume":"42","author":"Yilmaz","year":"2011","journal-title":"Arch Med Res"},{"key":"10.1016\/j.jacc.2018.11.050_bib47","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.jacc.2006.09.053","article-title":"Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine","volume":"49","author":"Yla-Herttuala","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.11.050_bib48","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jhep.2014.03.013","article-title":"Procoagulant imbalance in patients with non-alcoholic fatty liver disease","volume":"61","author":"Tripodi","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jacc.2018.11.050_bib49","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/nrgastro.2010.172","article-title":"The role of the gut microbiota in nonalcoholic fatty liver disease","volume":"7","author":"Abu-Shanab","year":"2010","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jacc.2018.11.050_bib50","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1146\/annurev-med-060513-093205","article-title":"The gut microbial endocrine organ: bacterially derived signals driving cardiometabolic diseases","volume":"66","author":"Brown","year":"2015","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jacc.2018.11.050_bib51","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.metabol.2015.09.017","article-title":"Non-alcoholic fatty liver disease and risk of cardiovascular disease","volume":"65","author":"Lonardo","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.jacc.2018.11.050_bib52","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/hep.27242","article-title":"Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis","volume":"61","author":"Smagris","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2018.11.050_bib53","doi-asserted-by":"crossref","first-page":"e74089","DOI":"10.1371\/journal.pone.0074089","article-title":"PNPLA3 GG genotype and carotid atherosclerosis in patients with non-alcoholic fatty liver disease","volume":"8","author":"Petta","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jacc.2018.11.050_bib54","doi-asserted-by":"crossref","first-page":"e39362","DOI":"10.1371\/journal.pone.0039362","article-title":"Paradoxical lower serum triglyceride levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the PNPLA3 148M variant","volume":"7","author":"Palmer","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jacc.2018.11.050_bib55","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/eurheartj\/ehx662","article-title":"Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: Mendelian randomization and meta-analysis of 279\u2009013 individuals","volume":"39","author":"Lauridsen","year":"2018","journal-title":"European Heart Journal"},{"key":"10.1016\/j.jacc.2018.11.050_bib56","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/ng.2901","article-title":"Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease","volume":"46","author":"Kozlitina","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.jacc.2018.11.050_bib57","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/hep.27490","article-title":"Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease","volume":"61","author":"Dongiovanni","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2018.11.050_bib58","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1038\/labinvest.2012.103","article-title":"Increased intrahepatic resistance in severe steatosis: endothelial dysfunction, vasoconstrictor overproduction and altered microvascular architecture","volume":"92","author":"Francque","year":"2012","journal-title":"Lab Invest"},{"key":"10.1016\/j.jacc.2018.11.050_bib59","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/hep.27869","article-title":"Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: a population-based study","volume":"62","author":"VanWagner","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2018.11.050_bib60","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jhep.2012.11.015","article-title":"Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease","volume":"58","author":"Hallsworth","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jacc.2018.11.050_bib61","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0016-5085(99)70506-8","article-title":"Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity","volume":"116","author":"Matteoni","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jacc.2018.11.050_bib62","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2005.04.014","article-title":"The natural history of nonalcoholic fatty liver disease: a population-based cohort study","volume":"129","author":"Adams","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jacc.2018.11.050_bib63","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/hep.23314","article-title":"Decreased survival of subjects with elevated liver function tests during a 28-year follow-up","volume":"51","author":"Soderberg","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2018.11.050_bib64","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.jacc.2016.01.070","article-title":"Nonalcoholic fatty liver disease and incident cardiac events: The Multi-Ethnic Study of Atherosclerosis","volume":"67","author":"Zeb","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.11.050_bib65","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1002\/hep.29546","article-title":"Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: a 20 year-community study","volume":"67","author":"Allen","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2018.11.050_bib66","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2018.11.050_bib67","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.2337\/dc07-0349","article-title":"Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients","volume":"30","author":"Targher","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2018.11.050_bib68","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1111\/j.1572-0241.2008.02034.x","article-title":"Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study","volume":"103","author":"Dunn","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jacc.2018.11.050_bib69","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jhep.2008.06.018","article-title":"Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease","volume":"49","author":"Ong","year":"2008","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jacc.2018.11.050_bib70","doi-asserted-by":"crossref","first-page":"d6891","DOI":"10.1136\/bmj.d6891","article-title":"Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study","volume":"343","author":"Lazo","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2018.11.050_bib71","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/hep.26156","article-title":"Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States","volume":"57","author":"Kim","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2018.11.050_bib72","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1161\/ATVBAHA.107.152298","article-title":"Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women's Heart and Health Study and Meta-Analysis","volume":"27","author":"Fraser","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2018.11.050_bib73","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","article-title":"Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis","volume":"65","author":"Targher","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jacc.2018.11.050_bib74","doi-asserted-by":"crossref","first-page":"S209","DOI":"10.1016\/j.dsx.2016.12.033","article-title":"Nonalcoholic fatty liver disease and the risk of clinical cardiovascular events: a systematic review and meta-analysis","volume":"11 Suppl 1","author":"Mahfood Haddad","year":"2017","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.jacc.2018.11.050_bib75","doi-asserted-by":"crossref","first-page":"33386","DOI":"10.1038\/srep33386","article-title":"Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and meta-analysis","volume":"6","author":"Wu","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jacc.2018.11.050_bib76","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jdiacomp.2016.09.008","article-title":"Non-alcoholic fatty liver disease is associated with late but not early atherosclerotic lesions in Chinese inpatients with type 2 diabetes","volume":"31","author":"Guo","year":"2017","journal-title":"J\u00a0Diabetes Complications"},{"key":"10.1016\/j.jacc.2018.11.050_bib77","doi-asserted-by":"crossref","first-page":"126","DOI":"10.4250\/jcu.2012.20.3.126","article-title":"Relationship between nonalcoholic fatty liver disease and carotid artery atherosclerosis beyond metabolic disorders in non-diabetic patients","volume":"20","author":"Kang","year":"2012","journal-title":"J\u00a0Cardiovasc Ultrasound"},{"key":"10.1016\/j.jacc.2018.11.050_bib78","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/hep.25593","article-title":"Nonalcoholic fatty liver disease is associated with coronary artery calcification","volume":"56","author":"Kim","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2018.11.050_bib79","doi-asserted-by":"crossref","first-page":"e0180118","DOI":"10.1371\/journal.pone.0180118","article-title":"Increased risk for development of coronary artery calcification in subjects with non-alcoholic fatty liver disease and systemic inflammation","volume":"12","author":"Kim","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jacc.2018.11.050_bib80","doi-asserted-by":"crossref","first-page":"3134","DOI":"10.1210\/jc.2016-1525","article-title":"Nonalcoholic fatty liver disease is associated with coronary artery calcification development: a longitudinal study","volume":"101","author":"Park","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.jacc.2018.11.050_bib81","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/gutjnl-2016-311854","article-title":"Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study","volume":"66","author":"Sinn","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.jacc.2018.11.050_bib82","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.2337\/dc12-0515","article-title":"Fatty liver, insulin resistance, and features of metabolic syndrome: relationships with coronary artery calcium in 10,153 people","volume":"35","author":"Sung","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2018.11.050_bib83","doi-asserted-by":"crossref","first-page":"9933","DOI":"10.1038\/s41598-017-09851-5","article-title":"Nonalcoholic fatty liver disease and coronary artery calcification in a northern chinese population: a cross sectional study","volume":"7","author":"Wu","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jacc.2018.11.050_bib84","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJMra0912063","article-title":"Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease","volume":"363","author":"Targher","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.11.050_bib85","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jhep.2008.06.012","article-title":"Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review","volume":"49","author":"Sookoian","year":"2008","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jacc.2018.11.050_bib86","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.dld.2016.09.002","article-title":"Nonalcoholic fatty liver disease is associated with coronary artery calcification: a systematic review and meta-analysis","volume":"48","author":"Jaruvongvanich","year":"2016","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jacc.2018.11.050_bib87","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/hep4.1155","article-title":"Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: a systematic review and meta-analysis","volume":"2","author":"Zhou","year":"2018","journal-title":"Hepatology Communications"},{"key":"10.1016\/j.jacc.2018.11.050_bib88","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/j.gastro.2016.06.001","article-title":"Persistent nonalcoholic fatty liver disease increases risk for carotid atherosclerosis","volume":"151","author":"Sinn","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jacc.2018.11.050_bib89","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/hep.28253","article-title":"Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: a prospective cohort study","volume":"63","author":"Wong","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2018.11.050_bib90","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1111\/hepr.12665","article-title":"Association of coronary artery calcification with liver fibrosis in Japanese patients with non-alcoholic fatty liver disease","volume":"46","author":"Ishiba","year":"2016","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jacc.2018.11.050_bib91","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1148\/radiol.14140933","article-title":"High-risk coronary plaque at coronary CT angiography is associated with nonalcoholic fatty liver disease, independent of coronary plaque and stenosis burden: results from the ROMICAT II trial","volume":"274","author":"Puchner","year":"2015","journal-title":"Radiology"},{"key":"10.1016\/j.jacc.2018.11.050_bib92","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1016\/j.amjcard.2017.07.107","article-title":"Effect of nonalcoholic fatty liver disease on in-hospital and long-term outcomes in patients with ST-segment elevation myocardial infarction","volume":"120","author":"Keskin","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2018.11.050_bib93","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.amjcard.2015.09.021","article-title":"Impact of nonalcoholic fatty liver disease on myocardial perfusion in nondiabetic patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction","volume":"116","author":"Emre","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2018.11.050_bib94","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijcard.2016.06.180","article-title":"Echocardiography and NAFLD (non-alcoholic fatty liver disease)","volume":"221","author":"Trovato","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2018.11.050_bib95","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1161\/ATVBAHA.112.300556","article-title":"Hepatic steatosis is associated with aortic valve sclerosis in the general population: the Study of Health in Pomerania (SHIP)","volume":"33","author":"Markus","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2018.11.050_bib96","doi-asserted-by":"crossref","first-page":"e88371","DOI":"10.1371\/journal.pone.0088371","article-title":"Nonalcoholic fatty liver disease is associated with aortic valve sclerosis in patients with type 2 diabetes mellitus","volume":"9","author":"Bonapace","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jacc.2018.11.050_bib97","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.metabol.2015.04.003","article-title":"Heart valve calcification in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"64","author":"Mantovani","year":"2015","journal-title":"Metabolism"},{"key":"10.1016\/j.jacc.2018.11.050_bib98","doi-asserted-by":"crossref","first-page":"e0162473","DOI":"10.1371\/journal.pone.0162473","article-title":"Epicardial adipose tissue (EAT) thickness is associated with cardiovascular and liver damage in nonalcoholic fatty liver disease","volume":"11","author":"Fracanzani","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jacc.2018.11.050_bib99","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jacl.2016.01.008","article-title":"Relationship of epicardial fat thickness and nonalcoholic fatty liver disease to coronary artery calcification: from the CAESAR study","volume":"10","author":"Kim","year":"2016","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.jacc.2018.11.050_bib100","first-page":"134","article-title":"Nonalcoholic fatty liver disease (NAFLD) and risk of cardiac arrhythmias: a new aspect of the liver-heart axis","volume":"5","author":"Mantovani","year":"2017","journal-title":"J\u00a0Clin Transl Hepatol"},{"key":"10.1016\/j.jacc.2018.11.050_bib101","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.amjcard.2012.09.021","article-title":"Relation of circulating liver transaminase concentrations to risk of new-onset atrial fibrillation","volume":"111","author":"Sinner","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2018.11.050_bib102","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1042\/CS20130036","article-title":"Non-alcoholic fatty liver disease is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes","volume":"125","author":"Targher","year":"2013","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.jacc.2018.11.050_bib103","doi-asserted-by":"crossref","first-page":"e57183","DOI":"10.1371\/journal.pone.0057183","article-title":"Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes","volume":"8","author":"Targher","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jacc.2018.11.050_bib104","doi-asserted-by":"crossref","first-page":"e0142937","DOI":"10.1371\/journal.pone.0142937","article-title":"Non-alcoholic fatty liver disease as a predictor of atrial fibrillation in middle-aged population (OPERA Study)","volume":"10","author":"K\u00e4r\u00e4j\u00e4m\u00e4ki","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jacc.2018.11.050_bib105","article-title":"Nonalcoholic fatty liver disease is associated with qt prolongation in the general population","volume":"4","author":"Hung","year":"2015","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2018.11.050_bib106","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.2337\/dc16-0091","article-title":"Nonalcoholic fatty liver disease is associated with ventricular arrhythmias in patients with type 2 diabetes referred for clinically indicated 24-hour Holter monitoring","volume":"39","author":"Mantovani","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2018.11.050_bib107","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41575-018-0010-0","article-title":"Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease","volume":"15","author":"Anstee","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jacc.2018.11.050_bib108","article-title":"Relations of liver fat with prevalent and incident atrial fibrillation in the framingham heart study","volume":"6","author":"Long","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2018.11.050_bib109","doi-asserted-by":"crossref","first-page":"5160754","DOI":"10.1155\/2016\/5160754","article-title":"Cardiovascular autonomic dysfunction in patients of nonalcoholic fatty liver disease","volume":"2016","author":"Kumar","year":"2016","journal-title":"Int J Hepatol"},{"issue":"25 Pt B","key":"10.1016\/j.jacc.2018.11.050_bib110","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1016\/j.jacc.2013.11.003","article-title":"2013 AHA\/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Eckel","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.11.050_bib111","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.amjcard.2014.09.044","article-title":"Relation of physical activity to prevalence of nonalcoholic Fatty liver disease independent of cardiometabolic risk","volume":"115","author":"Oni","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2018.11.050_bib112","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/MEG.0000000000000286","article-title":"Association between liver fibrosis and coronary heart disease risk in patients with nonalcoholic fatty liver disease","volume":"27","author":"Dogan","year":"2015","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jacc.2018.11.050_bib113","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jacc.2018.11.050_bib114","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/hep.30170","article-title":"Non-heavy drinking and worsening of non-invasive fibrosis markers in nonalcoholic fatty liver disease: a cohort study","volume":"69","author":"Chang","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2018.11.050_bib115","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.cgh.2018.01.026","article-title":"Among Patients With Nonalcoholic Fatty Liver Disease, Modest Alcohol Use Is Associated With Less Improvement in Histologic Steatosis and Steatohepatitis","volume":"16","author":"Ajmera","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jacc.2018.11.050_bib116","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.jacc.2010.01.006","article-title":"Alcohol consumption and mortality in patients with cardiovascular disease: a meta-analysis","volume":"55","author":"Costanzo","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.11.050_bib117","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/ajg.2010.102","article-title":"The myth of statin-induced hepatotoxicity","volume":"105","author":"Bader","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jacc.2018.11.050_bib118","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/hep.20671","article-title":"Statins and hepatotoxicity: focus on patients with fatty liver","volume":"41","author":"Chalasani","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2018.11.050_bib119","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.numecd.2016.09.011","article-title":"Under-prescription of statins in patients with non-alcoholic fatty liver disease","volume":"27","author":"Del Ben","year":"2017","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.jacc.2018.11.050_bib120","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jhep.2011.07.023","article-title":"Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing","volume":"56","author":"Bjornsson","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jacc.2018.11.050_bib121","doi-asserted-by":"crossref","first-page":"77c","DOI":"10.1016\/j.amjcard.2005.12.014","article-title":"An assessment of statin safety by hepatologists","volume":"97","author":"Cohen","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2018.11.050_bib122","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2018.11.050_bib123","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2018.11.050_bib124","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2018.11.050_bib125","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1161\/CIRCULATIONAHA.106.624890","article-title":"Risks associated with statin therapy: a systematic overview of randomized clinical trials","volume":"114","author":"Kashani","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.11.050_bib126","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1053\/j.gastro.2004.02.015","article-title":"Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity","volume":"126","author":"Chalasani","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jacc.2018.11.050_bib127","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2018.11.050_bib128","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jacl.2014.02.011","article-title":"The National Lipid Association's Statin Safety Task F. An assessment by the Statin Liver Safety Task Force: 2014 update","volume":"8","author":"Bays","year":"2014","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.jacc.2018.11.050_bib129","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/j.1872-034X.2011.00849.x","article-title":"Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: an open-label, pilot study","volume":"41","author":"Hyogo","year":"2011","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jacc.2018.11.050_bib130","doi-asserted-by":"crossref","first-page":"7860","DOI":"10.3748\/wjg.v21.i25.7860","article-title":"Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome","volume":"21","author":"Kargiotis","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jacc.2018.11.050_bib131","doi-asserted-by":"crossref","first-page":"e000075","DOI":"10.1136\/bmjgast-2015-000075","article-title":"Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease","volume":"3","author":"Nascimbeni","year":"2016","journal-title":"BMJ Open Gastroenterol"},{"key":"10.1016\/j.jacc.2018.11.050_bib132","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1755-5922.2009.00088.x","article-title":"Prescribing statins to patients with nonalcoholic fatty liver disease: real cardiovascular benefits outweigh theoretical hepatotoxic risk","volume":"27","author":"Riley","year":"2009","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.jacc.2018.11.050_bib133","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/S0140-6736(10)61272-X","article-title":"Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis","volume":"376","author":"Athyros","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2018.11.050_bib134","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1016\/j.ijcard.2013.06.024","article-title":"Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels","volume":"168","author":"Tikkanen","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2018.11.050_bib135","doi-asserted-by":"crossref","first-page":"796","DOI":"10.5114\/aoms.2011.25554","article-title":"Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study","volume":"7","author":"Athyros","year":"2011","journal-title":"Arch Med Sci"},{"issue":"25 Pt B","key":"10.1016\/j.jacc.2018.11.050_bib136","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.11.050_bib137","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/apt.12944","article-title":"Association between aspirin use and the prevalence of nonalcoholic fatty liver disease: a cross-sectional study from the Third National Health and Nutrition Examination Survey","volume":"40","author":"Shen","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jacc.2018.11.050_bib138","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1001\/archinte.1987.00370010065016","article-title":"Reye's syndrome in adults: diagnostic considerations","volume":"147","author":"Meythaler","year":"1987","journal-title":"Archives of internal medicine"},{"key":"10.1016\/j.jacc.2018.11.050_bib139","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s12020-013-0087-8","article-title":"Non-alcoholic fatty liver disease: a diabetologist's perspective","volume":"45","author":"Pappachan","year":"2014","journal-title":"Endocrine"},{"key":"10.1016\/j.jacc.2018.11.050_bib140","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1586\/17474124.2014.894880","article-title":"Metformin in the treatment of non-alcoholic fatty liver disease: safety, efficacy and mechanism","volume":"8","author":"Rouabhia","year":"2014","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jacc.2018.11.050_bib141","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1001\/jama.2011.520","article-title":"Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial","volume":"305","author":"Lavine","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2018.11.050_bib142","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2018.11.050_bib143","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.jacc.2006.12.048","article-title":"The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study","volume":"49","author":"Erdmann","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.11.050_bib144","doi-asserted-by":"crossref","first-page":"e013927","DOI":"10.1136\/bmjopen-2016-013927","article-title":"Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis","volume":"7","author":"Liao","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.jacc.2018.11.050_bib145","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A\u00a0placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.11.050_bib146","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2018.11.050_bib147","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.11.050_bib148","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis","volume":"177","author":"Musso","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jacc.2018.11.050_bib149","doi-asserted-by":"crossref","first-page":"538","DOI":"10.5604\/01.3001.0010.0284","article-title":"Meta-analysis of randomized controlled trials of pharmacologic agents in non-alcoholic steatohepatitis","volume":"16","author":"Said","year":"2017","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jacc.2018.11.050_bib150","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2165\/00002018-200932030-00002","article-title":"Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive","volume":"32","author":"Dormandy","year":"2009","journal-title":"Drug Saf"},{"key":"10.1016\/j.jacc.2018.11.050_bib151","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2018.11.050_bib152","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.11.050_bib153","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jacc.2016.06.007","article-title":"Cardiovascular effects of the new weight loss agents","volume":"68","author":"Vorsanger","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.11.050_bib154","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1002\/hep.20420","article-title":"Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis","volume":"40","author":"Yokohama","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2018.11.050_bib155","doi-asserted-by":"crossref","first-page":"942","DOI":"10.3748\/wjg.15.942","article-title":"Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis","volume":"15","author":"Georgescu","year":"2009","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jacc.2018.11.050_bib156","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJM200001203420302","article-title":"Vitamin E supplementation and cardiovascular events in high-risk patients","volume":"342","author":"Yusuf","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.11.050_bib157","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1001\/jama.293.11.1338","article-title":"Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial","volume":"293","author":"Lonn","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2018.11.050_bib158","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1001\/jama.2008.600","article-title":"Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial","volume":"300","author":"Sesso","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2018.11.050_bib159","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1007\/s11695-015-1691-x","article-title":"Bariatric surgery and non-alcoholic fatty liver disease: a systematic review of liver biochemistry and histology","volume":"25","author":"Bower","year":"2015","journal-title":"Obes Surg"},{"key":"10.1016\/j.jacc.2018.11.050_bib160","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1053\/j.gastro.2015.04.014","article-title":"Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients","volume":"149","author":"Lassailly","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jacc.2018.11.050_bib161","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1136\/heartjnl-2012-301778","article-title":"Bariatric surgery and cardiovascular outcomes: a systematic review","volume":"98","author":"Vest","year":"2012","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2018.11.050_bib162","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jacc.2017.12.014","article-title":"Metabolic surgery: weight loss, diabetes, and beyond","volume":"71","author":"Pareek","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.11.050_bib163","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2018.11.050_bib164","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/apt.14492","article-title":"Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis","volume":"47","author":"Hameed","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jacc.2018.11.050_bib165","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-alpha and -delta, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jacc.2018.11.050_bib166","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s00535-017-1415-1","article-title":"Current and future pharmacological therapies for NAFLD\/NASH","volume":"53","author":"Sumida","year":"2018","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.jacc.2018.11.050_bib167","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/hep.29477","article-title":"A\u00a0randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis","volume":"67","author":"Friedman","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2018.11.050_bib168","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0168-8278(18)30221-6","article-title":"Cenicriviroc treatment for adults with non-alcoholic steatohepatitis: year 2 analysis of the phase 2b CENTAUR Study (abstr)","volume":"68 Suppl 1","author":"Ratziu","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jacc.2018.11.050_bib169","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2017.09.021","article-title":"Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?","volume":"68","author":"Lonardo","year":"2018","journal-title":"J\u00a0Hepatol"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109719300166?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109719300166?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:20:35Z","timestamp":1760016035000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109719300166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":169,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0735109719300166"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2018.11.050","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nonalcoholic Fatty Liver Disease and\u00a0the\u00a0Heart","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2018.11.050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}